Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

24 mai 2018

09:00
Bionomics Limited (ASX:BNO) , a...

08:30
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with...

08:30
The addition of Cxbladder Monitor for bladder cancer surveillance has been shown to enable physicians to reduce the overall number of diagnostic tests being ordered, potentially reducing the total cost of monitoring and reducing complications related...

08:01
Les personnes ayant un IMC de plus de 30 et étant traitées par Saxenda® (liraglutide) pour la gestion du poids ont perdu 8,1 kg (17,9 lb) en moyenne après six mois d'essais cliniques en situation réelle, avec une combinaison de régime et d'exercice....

08:01
People with a BMI of over 30, treated with Saxenda® (liraglutide) for weight management, lost an average of 8.1 kg (17.9 lbs) after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week...

08:00
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for rare and common malignancies, today announced a clinical supply arrangement with Pharmacyclics through which Pharmacyclics supplies...

07:30
Stellar Biotechnologies, Inc. , a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancer, among other diseases, today announced that third-party trial results have...

07:14
Targovax ASA ("Targovax" or "the Company") (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the completion of the 32-patient phase I/II clinical trial evaluating TG01 in...

07:00
Significant technology advancements set stage for targeted, multi-generation suppression of disease-transmitting mosquitoes   Oxitec Ltd, a wholly owned subsidiary of Intrexon Corporation , announced that the newest addition to its Friendlytm...

07:00
Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company has completed enrollment in its Phase 2 study of PR022, Realm's...

07:00
Miracor Medical SA announced today the clinical results from the physician-sponsored OxAMI-PiCSO study were published in the EuroIntervention journal and presented at the Hotline session of the EuroPCR conference by Dr. Giovanni Luigi De Maria, MD,...

05:32
Antisense Therapeutics (the "Company" or "ANP") is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-reviewed medical journal, the European...

04:07
New research from Griffith University, Australia, published today in the Journal of Alternative and Complementary Medicine, shows a multispecies-probiotic formulation to improve the quality of life of hay fever patients. Study details  The...

02:00
ECI-006 is safe and well tolerated eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose cohort in its...

02:00
People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

00:01
Combining data from electronic health records with results from standardized depression questionnaires better predicts suicide risk in the 90 days following either mental health specialty or primary care outpatient visits, reports a team from the...


23 mai 2018

19:20
CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzenetm-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA...

17:34
Epigen Biosciences, Inc. announced today that it has entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease and...

14:18
A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers...

14:00
A research team from NUST MISIS and Pirogov Russian National Research Medical University (RNRMU) has successfully conducted preclinical trials of a new anticancer drug based on magnetite nanoparticles. In the test results, the lifetime of sick mice...

13:25
Creative Medical Technology Holdings announced today completion of its 3 day exhibition at the American Urology Association (AUA) meeting.  The Company's presentations where delivered by Dr. Alexander Gershman, Director of The Institute of Advanced...

12:01
Intrinsic Therapeutics, Inc., une société de dispositifs médicaux qui se consacre au traitement des pathologies des disques intervertébraux, a annoncé aujourd'hui la publication des résultats à deux ans d'un essai clinique de supériorité randomisé...

12:01
Intrinsic Therapeutics, Inc., a medical device company focusing on spinal disc therapies, today announced the publication of two-year results from a landmark, randomized, superiority clinical trial. The trial investigated the Barricaid Anular Closure...

09:56
Today MicroPort Scientific Corporation (HKSE: 0853) ("MicroPorttm") announced primary endpoint data at 12 months and QCA angiography data at 13 months from its TARGET All-Comers (TARGET AC) trial. The results of the TARGET AC trial demonstrated that...

09:49
Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for age-related diseases, announced that it is currently recruiting for a Phase 1 clinical trial to evaluate the safety and efficacy of its allogeneic Mesenchymal Stem...

09:00
A healthcare analysis presented today shows that a novel, catheter-based endovascular system for creating hemodialysis access offers important quality-of-life benefits and cost savings compared to the traditional surgical approach in end-stage renal...

08:17
Access Scientific, LLC announced completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARDtm technology....

08:00
Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for...

08:00
Vanda Pharmaceuticals Inc. (Vanda) today announced results from the JET Study (VP-VEC-162-2102), a 3-night transatlantic travel study of the effects of tasimelteon on Jet Lag Disorder. Tasimelteon was shown to be effective in treating Jet Lag...

07:00
Alkermes plc today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, May 29 ? June 1, 2018. The poster presentations will highlight data from the company's...

06:00
Abbott today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and fully...

04:00
ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients.  In addition, the company announced submission of an...


22 mai 2018

16:05
Windtree Therapeutics, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that the Company has received $0.7 million under a previously-awarded 2016 Phase II Small...

13:37
Prometic Sciences de la Vie Inc. (« Prometic ») a annoncé aujourd'hui une présentation orale de nouvelles données cliniques évaluant l'effet de son principal médicament candidat à...

13:31
Prometic Life Sciences Inc. (Prometic) today announced an oral presentation of new clinical data assessing the effect of its lead small molecule candidate, PBI-4050, on blood biomarkers for the treatment of idiopathic pulmonary fibrosis...

12:57
Wize Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting on May 2, 2018 in Honolulu,...

11:35
Equinox, the high-performance lifestyle leader, today unveiled a study led with researchers at the David Geffen School of Medicine at UCLA linking behavioral sleep coaching to wide-ranging exercise performance benefits. A first in clinical research,...

10:55
UsAgainstAlzheimer's Chairman George Vradenburg today issued the following statement regarding the termination of clinical trial testing of the Alzheimer's drug atabecestat by Janssen: "To each individual who participated in the atabecestat study...

10:14
Immunovia AB today announced that Linköping University Hospital is to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate...

09:30
Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to zolpidem ER (exploratory endpoint) Next-morning driving...

09:29
Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related conditions, announced that it has received a $750,000 grant from the Maryland Technology Development Corporation (TEDCO).  Longeveron will apply the...

09:03
Edwards Lifesciences Corporation , the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450...

09:00
Envisagenics, Inc., a New York based biotechnology company, announced today that it was awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH). This grant will provide $1.5 million over two...

08:30
On Thursday, May 17, Janssen announced the termination of the EARLY clinical trial investigating a BACE inhibitor, atabecestat. The goal of this research was to slow cognitive decline in people at risk of Alzheimer's dementia....

08:30
Ampio Pharmaceuticals, Inc. today announced a poster presentation on the mechanism of action of a component of Ampiontm will be presented at AAST and the most recent study of Ampion treatment of Severe Osteoarthritis of the Knee ( AP-007-B) has been...

08:30
Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful first-in-human implantation of its Alivio ReFlowtm Ventricular System for treatment of...

08:30
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz® (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.1 Taltz is the first and only...

08:05
Vast Therapeutics, Inc., formerly Novoclem Therapeutics, Inc. (the Company), a preclinical stage pharmaceutical company focused on delivering the power of nitric oxide (NO) in a synthetically derived powder-based form, announced today that the...

08:01
The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1...

08:00
Epic Sciences announced today that new data will be presented from studies utilizing its single cell sequencing of circulating tumor cells (CTCs) to determine differential and mutually exclusive mutational patterns associated with mismatch DNA damage...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17